ObsEva (NASDAQ:OBSV) Research Coverage Started at StockNews.com

StockNews.com assumed coverage on shares of ObsEva (NASDAQ:OBSV) in a research note issued to investors on Thursday morning. The brokerage issued a hold rating on the stock.

ObsEva Stock Performance

The firm’s 50 day moving average is $0.01. The company has a market cap of $7.94 million, a PE ratio of -0.11 and a beta of 0.68. ObsEva has a 1-year low of $0.08 and a 1-year high of $2.14.

About ObsEva

ObsEva SA is a clinical-stage biopharmaceutical company, which engages in the research and development of therapeutic treatments for women’s reproductive health and pregnancy. It offers biopharmaceutical drugs addressing conditions compromising pregnancy from conception to birth. The company was founded by Ernest Loumaye and André Chollet on November 14, 2012 and is headquartered in Geneva, Switzerland.